In vitro activity of apramycin against multidrug-, carbapenem- and aminoglycoside-resistant Enterobacteriaceae and Acinetobacter baumannii
© The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy..
OBJECTIVES: Widespread antimicrobial resistance often limits the availability of therapeutic options to only a few last-resort drugs that are themselves challenged by emerging resistance and adverse side effects. Apramycin, an aminoglycoside antibiotic, has a unique chemical structure that evades almost all resistance mechanisms including the RNA methyltransferases frequently encountered in carbapenemase-producing clinical isolates. This study evaluates the in vitro activity of apramycin against multidrug-, carbapenem- and aminoglycoside-resistant Enterobacteriaceae and Acinetobacter baumannii, and provides a rationale for its superior antibacterial activity in the presence of aminoglycoside resistance determinants.
METHODS: A thorough antibacterial assessment of apramycin with 1232 clinical isolates from Europe, Asia, Africa and South America was performed by standard CLSI broth microdilution testing. WGS and susceptibility testing with an engineered panel of aminoglycoside resistance-conferring determinants were used to provide a mechanistic rationale for the breadth of apramycin activity.
RESULTS: MIC distributions and MIC90 values demonstrated broad antibacterial activity of apramycin against Escherichia coli, Klebsiella pneumoniae, Enterobacter spp., Morganella morganii, Citrobacter freundii, Providencia spp., Proteus mirabilis, Serratia marcescens and A. baumannii. Genotypic analysis revealed the variety of aminoglycoside-modifying enzymes and rRNA methyltransferases that rendered a remarkable proportion of clinical isolates resistant to standard-of-care aminoglycosides, but not to apramycin. Screening a panel of engineered strains each with a single well-defined resistance mechanism further demonstrated a lack of cross-resistance to gentamicin, amikacin, tobramycin and plazomicin.
CONCLUSIONS: Its superior breadth of activity renders apramycin a promising drug candidate for the treatment of systemic Gram-negative infections that are resistant to treatment with other aminoglycoside antibiotics.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:74 |
|---|---|
| Enthalten in: |
The Journal of antimicrobial chemotherapy - 74(2019), 4 vom: 01. Apr., Seite 944-952 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Juhas, Mario [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
11048-13-8 |
|---|
| Anmerkungen: |
Date Completed 30.06.2020 Date Revised 09.01.2021 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/jac/dky546 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM29257519X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM29257519X | ||
| 003 | DE-627 | ||
| 005 | 20231225073418.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/jac/dky546 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0975.xml |
| 035 | |a (DE-627)NLM29257519X | ||
| 035 | |a (NLM)30629184 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Juhas, Mario |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a In vitro activity of apramycin against multidrug-, carbapenem- and aminoglycoside-resistant Enterobacteriaceae and Acinetobacter baumannii |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.06.2020 | ||
| 500 | |a Date Revised 09.01.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. | ||
| 520 | |a OBJECTIVES: Widespread antimicrobial resistance often limits the availability of therapeutic options to only a few last-resort drugs that are themselves challenged by emerging resistance and adverse side effects. Apramycin, an aminoglycoside antibiotic, has a unique chemical structure that evades almost all resistance mechanisms including the RNA methyltransferases frequently encountered in carbapenemase-producing clinical isolates. This study evaluates the in vitro activity of apramycin against multidrug-, carbapenem- and aminoglycoside-resistant Enterobacteriaceae and Acinetobacter baumannii, and provides a rationale for its superior antibacterial activity in the presence of aminoglycoside resistance determinants | ||
| 520 | |a METHODS: A thorough antibacterial assessment of apramycin with 1232 clinical isolates from Europe, Asia, Africa and South America was performed by standard CLSI broth microdilution testing. WGS and susceptibility testing with an engineered panel of aminoglycoside resistance-conferring determinants were used to provide a mechanistic rationale for the breadth of apramycin activity | ||
| 520 | |a RESULTS: MIC distributions and MIC90 values demonstrated broad antibacterial activity of apramycin against Escherichia coli, Klebsiella pneumoniae, Enterobacter spp., Morganella morganii, Citrobacter freundii, Providencia spp., Proteus mirabilis, Serratia marcescens and A. baumannii. Genotypic analysis revealed the variety of aminoglycoside-modifying enzymes and rRNA methyltransferases that rendered a remarkable proportion of clinical isolates resistant to standard-of-care aminoglycosides, but not to apramycin. Screening a panel of engineered strains each with a single well-defined resistance mechanism further demonstrated a lack of cross-resistance to gentamicin, amikacin, tobramycin and plazomicin | ||
| 520 | |a CONCLUSIONS: Its superior breadth of activity renders apramycin a promising drug candidate for the treatment of systemic Gram-negative infections that are resistant to treatment with other aminoglycoside antibiotics | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Aminoglycosides |2 NLM | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 650 | 7 | |a Carbapenems |2 NLM | |
| 650 | 7 | |a Nebramycin |2 NLM | |
| 650 | 7 | |a 11048-13-8 |2 NLM | |
| 650 | 7 | |a apramycin |2 NLM | |
| 650 | 7 | |a 388K3TR36Z |2 NLM | |
| 700 | 1 | |a Widlake, Emma |e verfasserin |4 aut | |
| 700 | 1 | |a Teo, Jeanette |e verfasserin |4 aut | |
| 700 | 1 | |a Huseby, Douglas L |e verfasserin |4 aut | |
| 700 | 1 | |a Tyrrell, Jonathan M |e verfasserin |4 aut | |
| 700 | 1 | |a Polikanov, Yury S |e verfasserin |4 aut | |
| 700 | 1 | |a Ercan, Onur |e verfasserin |4 aut | |
| 700 | 1 | |a Petersson, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Cao, Sha |e verfasserin |4 aut | |
| 700 | 1 | |a Aboklaish, Ali F |e verfasserin |4 aut | |
| 700 | 1 | |a Rominski, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Crich, David |e verfasserin |4 aut | |
| 700 | 1 | |a Böttger, Erik C |e verfasserin |4 aut | |
| 700 | 1 | |a Walsh, Timothy R |e verfasserin |4 aut | |
| 700 | 1 | |a Hughes, Diarmaid |e verfasserin |4 aut | |
| 700 | 1 | |a Hobbie, Sven N |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of antimicrobial chemotherapy |d 1981 |g 74(2019), 4 vom: 01. Apr., Seite 944-952 |w (DE-627)NLM000017701 |x 1460-2091 |7 nnns |
| 773 | 1 | 8 | |g volume:74 |g year:2019 |g number:4 |g day:01 |g month:04 |g pages:944-952 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/jac/dky546 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 74 |j 2019 |e 4 |b 01 |c 04 |h 944-952 | ||